Agilent Expands Portfolio of Probes for In Situ Hybridization
Agilent Technologies Inc. (NYSE: A) today announced the release of a range of new probes for in situ hybridization, a technique used in pathology laboratories to obtain information about gene expression.
The new probes address the need to cleanly and accurately interpret data from both fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH).
The new Agilent SureFISH probes include Break-Apart: MALT1, BCL2, BCL6, CCND1, MYC, IGH, Dual Fusion: IGH/CCND1, IGH/MYC, and IGH/BCL2.
The new CISH probes include (ASR) EBER RNA CISH and Kappa and Lambda mRNA CISH probes.
“Our CISH and SureFISH probes are manufactured with Agilent’s unique process, which uses synthetic oligonucleotides rather than the more common bacterial artificial chromosomes,” said Kamni Vijay, Agilent vice president and general manager of the company’s genomics division. “This innovative approach ensures high signal-to-noise ratios with a low background signal, making the interpretation of the data faster, easier, and more accurate.”
Vijay noted that Agilent’s new probes will bring the precision of oligonucleotide-based in situ hybridization into more laboratories.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide. Information about Agilent is available at www.agilent.com.